BlossomHill Therapeutics, Inc. (BLSM) Stock Price & Analysis

17 Followers

BLSM Stock Chart & Stats

$14.24-$0.22(5.48%)

At close: Nov 10 4:00 PM EST

Day’s Range: $12.77 - $14.56
52-Week Range: $11.02 - $27.99
Previous Close: $13.50
Volume: N/A
Average Volume (3M): 172.50K
Market Cap: $452.62M
Enterprise Value: N/A
Total Cash (Recent Filing): $95.38M
Total Debt (Recent Filing): $23.37M
Price to Earnings (P/E): ―
Beta: 0.88
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Clinical Response Potential

The SOLARA results provide meaningful clinical validation for BH-30643 in a hard-to-treat, heavily pretreated population with limited approved targeted options. Response, disease-control, treatment continuation, and tolerability data support continued development and potential differentiation.

Improved Funding Flexibility

The IPO materially improves near-term funding flexibility for a company advancing clinical programs without commercial revenue. Additional capital can support trials, regulatory work, and development milestones, while updated governance may strengthen the organizational platform for execution.

Focused Precision-oncology Pipeline

A development program spanning resistance mutations, treatment-naive patients, and combination settings gives BH-30643 several potential paths through clinical development. The planned global Phase 2 study also indicates a structured effort to expand the drug's addressable opportunity.

Bears Say

No Commercial Revenue

With no reported revenue, BlossomHill remains dependent on future clinical success, commercialization, or partnerships to establish an operating business. This leaves current financial performance structurally weak and makes progress toward breakeven dependent on uncertain development milestones.

Widening Operating Losses

The sharp expansion in net loss shows that research and operating investment is increasing faster than any current income base. Sustained losses can consume funding intended for pipeline advancement and increase the need for additional capital before products generate revenue.

Cash Burn And Balance-sheet Pressure

Heavy and rising cash burn, combined with deeply negative equity and higher debt, reduces financial resilience as the company funds clinical development. Continued reliance on external financing could constrain capital allocation and expose shareholders to future financing pressure.

BlossomHill Therapeutics, Inc. News

BlossomHill Therapeutics aligns with FDA on Phase 2 dose for BH-30643

BlossomHill Therapeutics (BLSM) announced the outcome of its End-of-Phase 1 meeting with the U.S. Food and Drug Administration regarding BH-30643 for the treatment of patients with advanced or metastatic epidermal

2d agoBLSM

BlossomHill Therapeutics enters CDx collaboration with Foundation Medicine

BlossomHill Therapeutics (BLSM) announced a collaboration with Foundation Medicine to develop a companion diagnostic assay, or CDx, for the EGFR C797S resistance mutation. The collaboration will leverage the ongoing Phase

2w agoBLSM

BlossomHill: Robust Emerging KRAS Franchise and Promising BH-501284 Data Support Unchanged $35 Price Target and Buy Rating

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on BlossomHill Therapeutics, Inc., with a price target of $35.00. Robert Burns has given his Buy

1M agoBLSM

BlossomHill Therapeutics presents preclinical data on BH-501284 at AACR

BlossomHill Therapeutics (BLSM) announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research, AACR, Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development,

1M agoBLSM

BlossomHill Therapeutics price target raised to $40 from $36 at Leerink

Leerink raised the firm’s price target on BlossomHill Therapeutics (BLSM) to $40 from $36 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source

1M agoBLSM

BlossomHill Therapeutics price target raised to $40 from $30 at Guggenheim

Guggenheim raised the firm’s price target on BlossomHill Therapeutics (BLSM) to $40 from $30 and keeps a Buy rating on the shares after the company reported Q2 results and provided

1M agoBLSM

Midday Fly By: Stocks fall as rate-hike bets boost bond yields

Stocks swung lower on Friday as Treasury yields rebounded and rekindled concerns of a deteriorating macroeconomic backdrop. The yield on the 10-year Treasury note rebounded above the 5% threshold as

1M agoMG ACN

BlossomHill Therapeutics reports Q2 EPS ($8.75) vs ($5.51) last year

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter,” said Jean Cui, Ph.D., Founder, President and Chief Executive

1M agoBLSM EARNINGS

BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on BlossomHill Therapeutics, Inc., with a price target of $32.00. Charles Zhu has given his Buy

1M agoBLSM

BlossomHill updates BH-30643 lung cancer trial results

BlossomHill Therapeutics, Inc. ( ($BLSM) ) has issued an announcement. On September 15, 2026, BlossomHill Therapeutics reported updated results from its ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small

1M ago8K BLSM

BlossomHill Therapeutics announces updated SOLARA trial data

BlossomHill Therapeutics (BLSM) announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancerm or NSCLC, patients with secondary epidermal growth factor receptor resistance

1M agoBLSM

Guggenheim starts BlossomHill Therapeutics with a Buy on pipeline potential

As previously reported, Guggenheim initiated coverage of BlossomHill Therapeutics (BLSM) with a Buy rating and $30 price target BlossomHill’s “precision oncology” pipeline has potential to generate “significant upside for shareholders,”

2M agoBLSM

BlossomHill Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of BlossomHill Therapeutics (BLSM) with an Outperform rating and $36 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

2M agoBLSM

BlossomHill Therapeutics completes IPO and updates governance

BlossomHill Therapeutics, Inc. ( ($BLSM) ) has issued an update. On August 10, 2026, BlossomHill Therapeutics, Inc. closed its initial public offering of 9,375,000 shares of common stock at $16.00

3M ago8K BLSM

BLSM FAQ

What was BlossomHill Therapeutics, Inc.’s price range in the past 12 months?

BlossomHill Therapeutics, Inc. lowest stock price was $11.02 and its highest was $27.99 in the past 12 months.

What is BlossomHill Therapeutics, Inc.’s market cap?

BlossomHill Therapeutics, Inc.’s market cap is $452.62M.

When is BlossomHill Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were BlossomHill Therapeutics, Inc.’s earnings last quarter?

BlossomHill Therapeutics, Inc. released its earnings results on Sep 18, 2026. The company reported -$8.75 earnings per share for the quarter, missing the consensus estimate of -$0.926 by -$7.824.

Is BlossomHill Therapeutics, Inc. overvalued?

According to Wall Street analysts BlossomHill Therapeutics, Inc.’s price is currently Undervalued.

Does BlossomHill Therapeutics, Inc. pay dividends?

BlossomHill Therapeutics, Inc. does not currently pay dividends.

What is BlossomHill Therapeutics, Inc.’s EPS estimate?

BlossomHill Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BlossomHill Therapeutics, Inc. have?

BlossomHill Therapeutics, Inc. has 31,784,908 shares outstanding.

What happened to BlossomHill Therapeutics, Inc.’s price movement after its last earnings report?

BlossomHill Therapeutics, Inc. reported an EPS of -$8.75 in its last earnings report, missing expectations of -$0.926. Following the earnings report the stock price went down -4.027%.

Which hedge fund is a major shareholder of BlossomHill Therapeutics, Inc.?

Currently, no hedge funds are holding shares in BLSM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

BlossomHill Therapeutics, Inc. Stock Smart Score

Outperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description